IMVEXXY™ (estradiol vaginal inserts) Approved for the Treatment of Moderate to Severe Dyspareunia

Posted on May 30, 2018

Read Story

Source: PR Newswire

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced that the United States Food and Drug Administration (FDA) has approved IMVEXXY™ (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.